Cover Image
市場調查報告書

骨關節炎:開發平台分析

Osteoarthritis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232841
出版日期 內容資訊 英文 270 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎:開發平台分析 Osteoarthritis - Pipeline Review, H1 2017
出版日期: 2017年03月08日 內容資訊: 英文 270 Pages
簡介

骨關節炎,是最常見的關節炎之一,是指軟骨,保護關節的材料損壞的慢性狀態。這成為骨頭互相摩擦的原因,導致僵硬、疼痛、關節動作低下。危險因子 有高齡,關節受傷,肥胖等。一般的症候,有關節的疼痛和僵硬,動了之後疼痛變得厲害,骨刺,吱嘎作響等。 治療為依據手、手腕、頭、背、膝、腰等損傷的關節狀態,進行藥物療法和運動。

本報告提供骨關節炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 骨關節炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Abiogen Pharma S.p.A.
  • Ablynx NV
  • Achelios Therapeutics, Inc.
  • Addex Therapeutics Ltd
  • Akari Therapeutics, Plc
  • Amura Holdings Limited
  • Arcarios BV
  • 旭化成製藥
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Asterias Biotherapeutics, Inc.
  • Axsome Therapeutics, Inc.
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd.
  • Cara Therapeutics, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Evgen Pharma PLC
  • Galapagos NV
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • IntelliCell BioSciences Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • K-Stemcell Co., Ltd.
  • Levolta Pharmaceuticals, Inc.
  • Medivir AB
  • Merck KGaA
  • Mesoblast Limited
  • Mor Research Application Ltd
  • NicOx S.A.
  • Nordic Bioscience A/S
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • Omeros Corporation
  • 小野藥品工業
  • OrthoCyte Corporation
  • Osteologix Holdings Plc
  • Pfizer Inc.
  • Pharmalink AB
  • PLx Pharma Inc.
  • ProteoThera, Inc.
  • Regeneus Ltd
  • ReqMed Company, Ltd.
  • Sanofi
  • 生化學工業
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • STELIS Biopharma Pvt. Ltd.
  • Stempeutics Research Private Limited
  • Symic Biomedical, Inc.
  • 武田藥品工業
  • TissueGene, Inc.
  • Upsher-Smith Laboratories, Inc.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Yuhan Corporation
  • Yungjin Pharm. Co., Ltd.
  • Zimmer Biomet Holdings, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (apocynin + paeonol)
  • (clodronate disodium + hyaluronic acid)
  • ABT-981
  • AlloJoin
  • AM-3701
  • AM-3876
  • Anatabine
  • 骨關節炎抑制劑
  • 骨關節炎 TGF-β1阻礙抗體
  • ARC-118
  • AS-001
  • ASP-7962
  • BNP-OA
  • BRM-421
  • CDX-085
  • celecoxib
  • CHND-1
  • CKD-941
  • clodronate disodium
  • CR-8357
  • CR-845
  • CRB-0017
  • CS-30MS02
  • DA-5202
  • DIS-BIO-EPS
  • DNX-314
  • 骨疾病、骨關節炎治療藥
  • 骨關節炎治療藥
  • 骨關節炎Renin Angiotensin抑制劑
  • 骨關節炎、骨折骨形成蛋白調整藥
  • 免疫學、代謝性疾病、肌肉骨骼障礙的PPAR-δ調整藥
  • duloxetine hydrochloride DR
  • fasitibant chloride
  • GLPG-1972
  • GQ-203
  • GQ-303
  • GSK-2394002
  • GZ-389988
  • JD-4000 Series
  • Kartogenin
  • KBP-056
  • ketoprofen
  • KM-278
  • LEVI-04
  • LH-023
  • LNA-043
  • MIV-711
  • 發炎性疾病、骨關節炎的單株抗體
  • 骨關節炎單株抗體抑制劑
  • MOR-106
  • MSBCAR-001
  • naproxcinod
  • NBS-101
  • NStride APS
  • OAX-1
  • ONO-4474
  • OTXCP-03
  • OTXCP-07
  • pentosan多硫酸鈉
  • 骨關節炎肽
  • piclidenoson
  • PL-1100
  • PRO-1
  • Progenza
  • 骨關節炎蛋白質
  • 骨關節炎、氣喘蛋白質
  • 類風濕性關節炎、骨關節炎蛋白質
  • 肥胖、骨關節炎、腎線維症、亞伯氏症候群 BMP-7活性蛋白質
  • PRX-167700
  • 骨關節炎組換肽
  • 骨關節炎、中樞神經IL-4/IL-10受體活性組換蛋白質
  • 骨關節炎IGF-1受體工作組換蛋白質
  • 骨質疏鬆症、骨關節炎PTH受體工作組換蛋白質
  • ReJoin
  • Salmon Calcitonin
  • SAR-396049
  • SB-061
  • SBL-005
  • SI-613
  • SM-04690
  • 變性性關節炎小分子
  • 骨關節炎小分子
  • 適合免疫學、血液學、神經疾病A2A促效劑
  • 骨關節炎MMP13抑制劑
  • 焦慮症、循環系統疾病、骨關節炎GPR22標靶藥物
  • 免疫學、代謝障礙、肌肉骨骼障礙小分子
  • 免疫學、肌肉骨骼障礙、代謝障礙小分子
  • 骨關節炎小分子
  • 免疫學、腸胃障礙、神經學、血液疾病TNFR1拮抗劑
  • 骨關節炎ADAMTS-5抑制劑
  • 骨關節炎補體系蛋白質抑制劑
  • 骨關節炎、骨質疏鬆症激化酵素抑制劑
  • 骨關節炎MMP-13抑制劑
  • sprifermin
  • 自體免疫疾病幹細胞療法
  • 中樞神經、CVS、皮膚疾病、免疫疾病n、代謝障礙幹細胞療法
  • 變性性關節炎幹細胞療法
  • 膝關節炎幹細胞療法
  • 多發性硬化症、類風濕性關節炎、骨關節炎、自閉症、肺支氣管發育不良、心臟衰竭、腦損傷性麻痺幹細胞療法
  • 骨關節炎幹細胞療法
  • 骨關節炎、真性糖尿病、急性肝功能衰竭心肺功能甦醒後疾病、神經退行性疾病幹細胞療法
  • Stempeucel
  • 關節炎基質細胞療法
  • Sulforadex
  • tonogenchoncel-L
  • TPX-100
  • TRBN-0224
  • UGP-302
  • VOLT-01
  • X-0002
  • XT-101
  • XT-150
  • YH-14619
  • YRA-1909
  • YY-1201
  • zoledronic acid
  • ZYN-002
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9151IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 7
  • List of Figures 9
  • Introduction 10
  • Global Markets Direct Report Coverage 10
  • Osteoarthritis - Overview 11
  • Osteoarthritis - Therapeutics Development 12
  • Pipeline Overview 12
  • Pipeline by Companies 13
  • Pipeline by Universities/Institutes 19
  • Products under Development by Companies 20
  • Products under Development by Universities/Institutes 26
  • Osteoarthritis - Therapeutics Assessment 27
  • Assessment by Target 27
  • Assessment by Mechanism of Action 30
  • Assessment by Route of Administration 33
  • Assessment by Molecule Type 35
  • Osteoarthritis - Companies Involved in Therapeutics Development 37
  • A. Menarini Industrie Farmaceutiche Riunite Srl 37
  • AbbVie Inc 37
  • Abiogen Pharma SpA 38
  • Ablynx NV 38
  • Achelios Therapeutics Inc 39
  • Addex Therapeutics Ltd 39
  • Amgen Inc 40
  • Amura Holdings Ltd 40
  • Arcarios BV 41
  • Asahi Kasei Pharma Corp 41
  • Asklepios BioPharmaceutical Inc 42
  • Astellas Pharma Inc 42
  • Biopharm GmbH 43
  • Bone Therapeutics SA 43
  • Can-Fite BioPharma Ltd 44
  • Cardax Inc 44
  • Cellular Biomedicine Group Inc 45
  • Cipla Ltd 45
  • Corestem Inc 46
  • Dong-A Socio Holdings Co Ltd 46
  • Evgen Pharma Plc 47
  • F. Hoffmann-La Roche Ltd 47
  • Galapagos NV 48
  • Gemphire Therapeutics Inc 48
  • GeneFrontier Corp 49
  • Genequine Biotherapeutics GmbH 49
  • GlaxoSmithKline Plc 50
  • HSRx Group 50
  • InKemia IUCT Group SA 51
  • International Stem Cell Corp 51
  • Jeil Pharmaceutical Co Ltd 52
  • Jenrin Discovery Inc 52
  • K-Stemcell Co Ltd 53
  • Kang Stem Biotech Co Ltd 53
  • Levolta Pharmaceuticals Inc 54
  • LG Chem, Ltd. 54
  • Marina Biotech Inc 55
  • Medivir AB 55
  • Merck KGaA 56
  • Mesoblast Ltd 56
  • Mor Research Application Ltd 57
  • NicOx SA 57
  • Nordic Bioscience A/S 58
  • Novartis AG 58
  • NovelMed Therapeutics Inc 59
  • Omeros Corp 59
  • Ono Pharmaceutical Co Ltd 60
  • OrthoCyte Corp 60
  • Osteologix Holdings Plc 61
  • Pfizer Inc 61
  • Pharmalink AB 62
  • Philogen SpA 62
  • PhytoHealth Corp 63
  • PLx Pharma Inc 63
  • ProteoThera Inc 64
  • Regeneus Ltd 64
  • Regulaxis SAS 65
  • Rottapharm Biotech Srl 65
  • Samumed LLC 66
  • Seikagaku Corp 66
  • Stelis Biopharma Pvt Ltd 67
  • Takeda Pharmaceutical Company Ltd 67
  • TissueGene Inc 68
  • Yooyoung Pharmaceutical Co Ltd 68
  • Yuhan Corp 69
  • Yungjin Pharm Co Ltd 69
  • Zimmer Biomet Holdings Inc 70
  • Osteoarthritis - Drug Profiles 71
  • (clodronate disodium + hyaluronic acid) - Drug Profile 71
  • (methylprednisolone + zoledronic acid) - Drug Profile 72
  • 4-P004 - Drug Profile 74
  • ABT-981 - Drug Profile 75
  • ALLO-ASC - Drug Profile 76
  • AlloJoin - Drug Profile 78
  • AM-3701 - Drug Profile 79
  • AM-3876 - Drug Profile 80
  • Anatabine - Drug Profile 81
  • Antibody for Osteoarthritis - Drug Profile 84
  • Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 85
  • apocynin + paeonol - Drug Profile 86
  • ARC-118 - Drug Profile 87
  • AS-001 - Drug Profile 88
  • BNP-OA - Drug Profile 89
  • CDX-085 - Drug Profile 90
  • celecoxib - Drug Profile 93
  • Cell Therapy for Osteoarthritis - Drug Profile 94
  • Chondrostem - Drug Profile 95
  • clodronate disodium - Drug Profile 96
  • CMX-020 - Drug Profile 97
  • CR-8357 - Drug Profile 98
  • CRB-0017 - Drug Profile 99
  • CS-30MS02 - Drug Profile 100
  • DA-5202 - Drug Profile 101
  • denosumab - Drug Profile 102
  • DIS-BIO-EPS - Drug Profile 112
  • DNX-314 - Drug Profile 113
  • Drug for Bone Diseases and Osteoarthritis - Drug Profile 114
  • Drug for Osteoarthritis - Drug Profile 115
  • Drug for Osteoarthritis - Drug Profile 116
  • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 117
  • Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 118
  • fasitibant chloride - Drug Profile 119
  • gemcabene calcium - Drug Profile 120
  • GFC-301 - Drug Profile 124
  • GLPG-1972 - Drug Profile 125
  • GQ-203 - Drug Profile 126
  • GQ-303 - Drug Profile 127
  • GSK-2394002 - Drug Profile 128
  • JD-4000 Series - Drug Profile 129
  • Jointstem - Drug Profile 130
  • JTA-004 - Drug Profile 132
  • Kartogenin - Drug Profile 133
  • KBP-056 - Drug Profile 134
  • ketoprofen - Drug Profile 135
  • LEVI-04 - Drug Profile 137
  • LH-021 - Drug Profile 138
  • LNA-043 - Drug Profile 139
  • MIV-711 - Drug Profile 140
  • Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile 143
  • Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile 144
  • Monoclonal Antibody for Osteoarthritis - Drug Profile 145
  • MPC-75IA - Drug Profile 146
  • naproxcinod - Drug Profile 147
  • NBS-101 - Drug Profile 150
  • NStride APS - Drug Profile 152
  • ONO-4474 - Drug Profile 153
  • OTXCP-03 - Drug Profile 154
  • OTXCP-07 - Drug Profile 155
  • PF-152 - Drug Profile 156
  • PHDC-02 - Drug Profile 157
  • piclidenoson - Drug Profile 158
  • PL-1100 - Drug Profile 167
  • PN-6047 - Drug Profile 168
  • PRO-1 - Drug Profile 169
  • Progenza - Drug Profile 170
  • Protein for Osteoarthritis and Asthma - Drug Profile 172
  • Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 173
  • PRX-167700 - Drug Profile 174
  • Recombinant Protein for Osteoarthritis - Drug Profile 176
  • Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 177
  • Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 179
  • Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 180
  • Reg-O3 - Drug Profile 181
  • ReJoin - Drug Profile 182
  • salmon calcitonin - Drug Profile 186
  • SBL-005 - Drug Profile 188
  • SFX-01 - Drug Profile 189
  • SI-613 - Drug Profile 192
  • SM-04690 - Drug Profile 193
  • Small Molecule for Degenerative Arthritis - Drug Profile 196
  • Small Molecule for Osteoarthritis - Drug Profile 197
  • Small Molecule for Osteoarthritis - Drug Profile 198
  • Small Molecule for Osteoarthritis - Drug Profile 199
  • Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 200
  • Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 201
  • Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 202
  • Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 203
  • Small Molecules for Osteoarthritis - Drug Profile 204
  • Small Molecules for Osteoarthritis - Drug Profile 205
  • Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 206
  • Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile 207
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 208
  • sprifermin - Drug Profile 209
  • Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile 211
  • Stem Cell Therapy for Autoimmune Diseases - Drug Profile 212
  • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 214
  • Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 215
  • Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile 216
  • Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile 217
  • Stempeucel - Drug Profile 218
  • tonogenchoncel-L - Drug Profile 221
  • TPX-100 - Drug Profile 224
  • TRBN-0224 - Drug Profile 226
  • UGP-302 - Drug Profile 228
  • VA-694 - Drug Profile 230
  • X-0002 - Drug Profile 231
  • XT-101 - Drug Profile 233
  • XT-150 - Drug Profile 234
  • YH-14619 - Drug Profile 235
  • YRA-1909 - Drug Profile 236
  • YY-1201 - Drug Profile 237
  • YYD-302 - Drug Profile 238
  • Osteoarthritis - Dormant Projects 239
  • Osteoarthritis - Discontinued Products 246
  • Osteoarthritis - Product Development Milestones 248
  • Featured News & Press Releases 248
  • Appendix 261
  • Methodology 261
  • Coverage 261
  • Secondary Research 261
  • Primary Research 261
  • Expert Panel Validation 261
  • Contact Us 261
  • Disclaimer 262

List of Tables

  • Number of Products under Development for Osteoarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
  • Osteoarthritis - Pipeline by AbbVie Inc, H1 2017
  • Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017
  • Osteoarthritis - Pipeline by Ablynx NV, H1 2017
  • Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Osteoarthritis - Pipeline by Amgen Inc, H1 2017
  • Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017
  • Osteoarthritis - Pipeline by Arcarios BV, H1 2017
  • Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
  • Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017
  • Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017
  • Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017
  • Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Osteoarthritis - Pipeline by Cardax Inc, H1 2017
  • Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Osteoarthritis - Pipeline by Cipla Ltd, H1 2017
  • Osteoarthritis - Pipeline by Corestem Inc, H1 2017
  • Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017
  • Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Osteoarthritis - Pipeline by Galapagos NV, H1 2017
  • Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017
  • Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017
  • Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Osteoarthritis - Pipeline by HSRx Group, H1 2017
  • Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017
  • Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017
  • Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017
  • Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
  • Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017
  • Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017
  • Osteoarthritis - Pipeline by Medivir AB, H1 2017
  • Osteoarthritis - Pipeline by Merck KGaA, H1 2017
  • Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017
  • Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017
  • Osteoarthritis - Pipeline by NicOx SA, H1 2017
  • Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017
  • Osteoarthritis - Pipeline by Novartis AG, H1 2017
  • Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017
  • Osteoarthritis - Pipeline by Omeros Corp, H1 2017
  • Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017
  • Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017
  • Osteoarthritis - Pipeline by Pfizer Inc, H1 2017
  • Osteoarthritis - Pipeline by Pharmalink AB, H1 2017
  • Osteoarthritis - Pipeline by Philogen SpA, H1 2017
  • Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017
  • Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017
  • Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017
  • Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017
  • Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017
  • Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017
  • Osteoarthritis - Pipeline by Samumed LLC, H1 2017
  • Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017
  • Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
  • Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Osteoarthritis - Pipeline by TissueGene Inc, H1 2017
  • Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Yuhan Corp, H1 2017
  • Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Osteoarthritis - Discontinued Products, H1 2017
  • Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Osteoarthritis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top